Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Guselkumab demonstrated strong efficacy in treating moderate to severe scalp psoriasis, especially in individuals with skin of color, achieving nearly 70% complete scalp clearance by week 48. The ...

Psoriasis isn’t just a skin condition — it’s an autoimmune disease that can affect your whole body and wellbeing. From medical treatments to lifestyle changes, there are more ways than ever to manage ...

Moderate to severe scalp psoriasis severely affects quality of life, with high DLQI scores and significant symptoms like itch, pain, and flaking. Deucravacitinib, a tyrosine kinase 2 inhibitor, ...

The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque psoriasis of the scalp in a phase 3 study. This study excluded patients with predominantly ...

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Deucravacitinib maintained efficacy and safety when ...

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...

Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...